Study of ILUMYA and HALOG Ointment for Treating Moderate to Severe Plaque Psoriasis in Adults

What this Trial Is About

This research aims to evaluate the use of Ilumya, with or without Halog ointment, in adults with moderate to severe plaque psoriasis. The study focuses on patients who have this chronic skin condition characterized by widespread plaques and aims to assess the effectiveness and safety of combining these treatments. Participants will receive Ilumya injections of 100mg under the skin at the start of the study, week 4, and week 16. At week 16, if patients still have 3% or more of their body surface area affected by psoriasis, they will add Halog ointment 0.1%, applied twice daily for four weeks. Those with less than 3% affected will continue only with Ilumya. Follow-up visits will occur at weeks 20 and 24 to monitor progress. Throughout the study, participants will be regularly evaluated for changes in their affected skin area and overall condition. Researchers will measure body surface area affected by psoriasis at 16 weeks as the main outcome. Safety and effectiveness will be monitored until week 24. The total involvement spans from the initial treatment through the follow-up visits over 24 weeks.

ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.